Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain

NCT: NCT07568015 · NOT_YET_RECRUITING

NCT IDNCT07568015
StatusNOT_YET_RECRUITING
Start Date2026-05-01
Completion2029-11-01

Brief Summary

The goal of this clinical trial is to evaluate the safety and analgesic performance of the ReneuRx™ device in subjects with moderate to severe chronic lateral hip pain compared to subjects receiving treatment with corticosteroid injection in adults aged 22-80 years. Participants will attend study visits and complete quality of life questionnaires. Participants will be followed for approximately 6-12 months after the study procedure.

Frequently Asked Questions

What is ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain?

ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain is a clinical trial registered under NCT07568015. Current status: NOT_YET_RECRUITING.

What is the status of NCT07568015?

The current status of NCT07568015 (ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain) is: NOT_YET_RECRUITING.

When did ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain start?

ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain started on 2026-05-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.